An interventional study of Encora Pulse in Essential Tremor and Parkinson's Disease, sponsored by Encora, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Encora, Inc. · Not applicable, Interventional, and Treatment
Subjects will receive prototype devices to be used for participation. The study comprises three phases:
Inclusion Criteria - Alpha and Beta Phase B1
Exclusion Criteria - Alpha and Beta Phase B1
Inclusion Criteria - Beta Phase B2
Exclusion Criteria - Beta Phase B2
Oder of assessment begins with TETRAS and ends with ADLs
Device: Encora Pulse
Order of assessment begins with ADLs and ends with TETRAs
Device: Encora Pulse
Order of assessment begins with TETRAS and ends with ADLs, but both are administered backwards
Device: Encora Pulse
Order of assessment begins with ADLs and ends with TETRAs, but both are administered backwards
Device: Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist. This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
Assess the design changes between the alpha and beta versions of the device
This outcome measure assesses participants' experiences through an open-ended survey. Participants will be asked to describe their perceptions, symptoms, and overall experiences with the treatment. No predefined responses are given, and answers will be analyzed qualitatively
Time frame: Data will be collected at baseline and visit one.
To assess the usability of the beta device in an at-home setting
Characterization of any unforeseen errors during subject interaction with the packaging device and instructions for use during at-home use will be collected using the usability survey which is an open ended, qualitative survey that measures patient usage error and device related satisfaction
Time frame: Data will be collected at baseline, week 1, week 2, month 1, month 2 and month 3.
To establish the quantitative efficacy in upper limb tremor reduction using the BF-ADL scale
The Bain and Findley Tremor ADL Scale (BF-ADL) is a tool used to assess the impact of essential tremor on a person's ability to perform activities of daily living (ADLs), specifically those involving the upper limbs. The effectiveness of the device in reducing limb tremor will be evaluated using the BF-ADL scale. The scale rates each activity on a 1-to-4 scale: 1 indicates the activity can be done without difficulty, 2 with little effort, 3 with a lot of effort, and 4 means the activity cannot be done alone.
Time frame: Data will be collected at baseline, week 1, week 2, month 1, month 2 and month 3.
To establish the quantitative efficacy in upper limb tremor reduction using the TETRAS scale
The effectiveness of the device in reducing limb tremor will be evaluated using the TETRAS (Tremor Research Group Essential Tremor Rating Assessment Scale) tool. Tremor severity will be measured on a scale of 0 to 4; a score of 0 indicates no tremor, while a score of 4 represents severe tremor. Scores between 0 and 4 can be assigned using increments of 0.5, allowing for a more nuanced assessment of tremor severity.
Time frame: Data will be collected at baseline, week 1, week 2, month 1, month 2 and month 3.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Encora, Inc.